HHS Advisory Opinion Rejects Drug Manufacturers’ Attempts to Limit Contract Pharmacy Use by 340B Covered Entities
By EsqSocial Corporation 11/01/21
On December 30, 2020, the HHS Office of General Counsel (OGC) issued Advisory Opinion No. 20-06 finding the 340B Federal Drug Pricing Program requires drug manufacturers to extend 340B pricing to covered outpatient drugs dispensed through contract pharmacies. Recently, certain drug manufacturers have declined to distribute covered outpatient drugs through contract pharmacies at 340B pricing......
By: King & Spalding